title: Testosterone replacement attenuates haloperidol-induced catalepsy in male rats.
abstract: OBJECTIVE
  Parkinson's disease (PD) is a progressive neurodegenerative disease. Recent studies have indicated a higher prevalence of PD in male gender. Furthermore testosterone deficiency is more common among male parkinsonians in compare to healthy men. This study was aimed to investigate the effect of testosterone on catalepsy, in male rats.
  
  
  METHODS
  The study carried out on male Wistar rats. To induce catalepsy, haloperidol (1 mg/kg, i.p) as D2 antagonist was administered before testing animals via Bar test. Animals were gonadectomized to investigate testosterone elimination effect on catalepsy, and also the androgen receptor blocker, flutamide, and the aromatase inhibitor, letrozole, were administered in certain groups of animals. The bar test method was used to evaluate haloperidol-induced catalepsy.
  
  
  RESULTS
  Haloperidol 1 mg/kg, i.p, was able to induce catalepsy. Gonadectomy worsened the catalepsy and subchronic testosterone replacement could restore this effect to the level of normal animals. While low dose of flutamide administration represented an improvement in cataleptic symptoms, higher doses worsened catalepsy. Letrozole(4mg/kg,sc) administered animals represented nearly the same cataleptic symptoms as the control group.
  
  
  CONCLUSIONS
  Testosterone deficiency increases catalepsy and testosterone replacement can significantly be effective in catalepsy remission. It seems that the anticataleptic effect of testosterone is exerted through affecting on androgenic receptors.
authors.affiliation: Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
authors.forename: Naime
authors.initials: N
authors.lastname: Majidi Zolbanin
authors.affiliation: Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
authors.forename: Elmira
authors.initials: E
authors.lastname: Zolali
authors.affiliation: Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
authors.forename: Alireza
authors.initials: A
authors.lastname: Mohajjel Nayebi
keywords: Bar test; Catalepsy; Haloperidol; Parkinson’s disease; Testosterone
references.citation: Arch Neurol. 2006 May;63(5):729-35
references.pmid: 16682542
references.citation: J Clin Neurosci. 2006 Jan;13(1):133-6
references.pmid: 16410216
references.citation: J Neurol. 2000 Apr;247 Suppl 2:II95-102
references.pmid: 10991672
references.citation: Int Rev Cell Mol Biol. 2010;281:229-66
references.pmid: 20460187
references.citation: Horm Behav. 2006 Jun;50(1):27-32
references.pmid: 16473354
references.citation: Front Neuroendocrinol. 2009 Jul;30(2):142-57
references.pmid: 19410597
references.citation: Adv Pharm Bull. 2012;2(1):127-31
references.pmid: 24312782
references.citation: Brain Res. 1996 Apr 9;715(1-2):113-8
references.pmid: 8739629
references.citation: Daru. 2010;18(1):41-5
references.pmid: 22615592
references.citation: J Neurol Neurosurg Psychiatry. 2007 Aug;78(8):819-24
references.pmid: 17098842
references.citation: Boll Soc Ital Biol Sper. 1983 Jan 31;59(1):51-7
references.pmid: 6303368
references.citation: Behav Brain Res. 2000 May;109(2):207-12
references.pmid: 10762690
references.citation: Cell Tissue Res. 2004 Oct;318(1):215-24
references.pmid: 15503155
references.citation: Adv Pharm Bull. 2012;2(2):149-55
references.pmid: 24312786
references.citation: Biomed Pharmacother. 1999 Apr;53(3):117-21
references.pmid: 10349507
references.citation: J Neurol. 2005 Oct;252(10):1201-5
references.pmid: 16151602
references.citation: Pharmacol Biochem Behav. 1999 Nov;64(3):467-71
references.pmid: 10548257